SKYRIZI® (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada’s Drug ...

SKYRIZI® (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada’s Drug ...

Michigan’s Republican House Speaker Matt Hall has come under fire for receiving tickets to a Detroit Lions game supplied by a ...

There have been numerous legal, political and clinical developments in the anesthesia field in the last year that have significant implications for both patients, providers and healthcare ...

Hospital groups warn the 340B rebate pilot would force safety-net providers to front tens of millions for drugs and drain ...

"Because Chapter 70 is not adequately keeping pace, all education in low-income communities becomes unsustainable in a few ...

AT&T is dismantling its diversity, equity, and inclusion (DEI) programs, citing a changed legal landscape and a renewed focus ...

AbbVie (ABBV) has announced two updates for Canadians living with ulcerative colitis. Canada’s Drug Agency has recommended ...

The law was designed to rein in pharmacy benefit managers and stabilize local pharmacies, but officials say limited oversight and slow implementation have blunted its impact.

A central concern stems from the safeguards in place for supplemental learning funds, which due to IHLA’s public status, come ...

Lexicon Pharmaceuticals, Inc. currently offers three late-stage assets Zynquista, Inpefa & Pilavapadin. Learn more about LXRX ...

The American Medical Association is facing heightened scrutiny from Republican lawmakers about its role in shaping physician payment, The Washington Post reported Dec. 2. Five things to know: 1. Sen.